Relentless Health Value

Speaking of Infusions, Do You Want to Pay $135 or Do You Want to Pay $13,560 for the Exact Same Drug? With Ivana Krajcinovic, PhD

Feb 26, 2026

Two members of a plan received infusions at a hospital. If they had gone down the street, the plan would have spent $1 million less — for the same drug. That is the infusion nonmarket in 2026.

In this episode, Stacey Richter speaks with Ivana Krajcinovic, the outgoing Vice President of Healthcare Delivery at UNITE...

Why the Commercial Carrier Market Never Changes — Six Reasons There Is No Market

Feb 19, 2026

If you rank California's commercial health plans by member count and check back every year for 14 years, the ranking barely moves. Kaiser at the top. The big blues plans close behind. Everyone else exactly where they were. This is not a competitive market. It is a stalemate. And the stalemate has causes.

In this episode...

EP500: This Is Episode 500, and It’s All About You, Tribe

Feb 12, 2026

Ten years ago, Stacey Richter started Relentless Health Value because the healthcare industry felt like a Pachinko machine — you drop a program or a policy in, it bounces around a black box, and sometimes the result is the opposite of what you intended. Then she met the Relentless Tribe, who turned out to be the...

Self-insured Employers and Other Plan Sponsors Are Paying Millions for MSK (Musculoskeletal) Injuries That Would Have Healed Themselves, With Jay Kimmel, MD

Feb 5, 2026

Plan Sponsors Are Paying Millions for MSK Injuries That Would Have Healed Themselves — Here's Why

Musculoskeletal spend runs roughly $16 PMPM and accounts for 20–30% of total plan costs depending on member demographics — making it the third most costly category of spend. About 80% of those MSK injuries are low or...